Dr. Reddy's Laboratories Limited (RDY)
- Previous Close
69.30 - Open
69.18 - Bid 68.22 x 1000
- Ask 68.77 x 900
- Day's Range
68.17 - 69.09 - 52 Week Range
53.88 - 77.72 - Volume
201,365 - Avg. Volume
199,917 - Market Cap (intraday)
11.57B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
17.02 - EPS (TTM)
4.01 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield 0.49 (0.71%)
- Ex-Dividend Date Jul 7, 2023
- 1y Target Est
80.90
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
www.drreddys.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: RDY
Performance Overview: RDY
Trailing total returns as of 5/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RDY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RDY
Valuation Measures
Market Cap
11.57B
Enterprise Value
10.81B
Trailing P/E
17.02
Forward P/E
19.76
PEG Ratio (5yr expected)
3.44
Price/Sales (ttm)
3.40
Price/Book (mrq)
3.36
Enterprise Value/Revenue
3.23
Enterprise Value/EBITDA
10.20
Financial Highlights
Profitability and Income Statement
Profit Margin
19.95%
Return on Assets (ttm)
11.67%
Return on Equity (ttm)
21.77%
Revenue (ttm)
279.16B
Net Income Avi to Common (ttm)
55.68B
Diluted EPS (ttm)
4.01
Balance Sheet and Cash Flow
Total Cash (mrq)
81.47B
Total Debt/Equity (mrq)
7.14%
Levered Free Cash Flow (ttm)
15.07B
Research Analysis: RDY
Company Insights: RDY
RDY does not have Company Insights